In this video, 3 experts share what makes the Worldwide Clinical Trials Early Phase Program, including the Bioanalytical Lab and Clinical Pharmacology Unit, different.

With so many regulations and so much confusion around biosimilars, it can often feel like patients have to choose between death or financial burden. Work with a CRO that can help you achieve the best biosimilar development program. Watch our latest webinar now to learn more.

In the following article by North Carolina Biotechnology Center, Dr. Elizabeth Witherspoon, NCBiotech Writer, discusses the strategic partnership between Worldwide and Deep Lens to utilize AI technology and develop a greater oncology focus in order to address rapidly changing trial needs.

In the following article by the Journal for Clinical Studies, Worldwide’s Dr. Michael Murphy, Chief Medical and Scientific Officer, and Barbara Zupancic, Senior Director of Patient Recruitment and Retention, discuss the elements of a patient-centric trial design, in addition to high-quality patient engagement and its impact on orphan drug success.

Co-Founder and COO of Compass Pathways, Lars Wilde, discusses his journey to secure funding for his psilocybin therapy for treatment-resistant depression. What made him so successful? Listen now to find out.

In the following Triangle Business Journal article, Worldwide’s Gaurav Sharma, Senior Vice President of Rare Disease and Oncology, discusses the recent expansion to Worldwide’s oncology unit, in addition to new, enhanced capabilities.